Atrantil for Intestinal Bacterial Overgrowth
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing Atrantil, a natural supplement made from peppermint, quebracho tree bark, and horse chestnut. It targets patients with Intestinal Methanogenic Overgrowth (IMO), who suffer from excessive methane production in their gut. Atrantil aims to reduce methane gas, which can help relieve symptoms like bloating and constipation.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Who Is on the Research Team?
Darren Brenner, MD
Principal Investigator
Northwestern Memorial Hospital/Feinberg School of Medicine
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants take two capsules of Atrantil three times a day for 28 days
Follow-up
Participants are monitored for changes in quality of life and clinical symptoms after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Atrantil
Find a Clinic Near You
Who Is Running the Clinical Trial?
Northwestern University
Lead Sponsor